{"resourceType": "Composition", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"], "versionId": "4", "lastUpdated": "2025-12-11T11:42:09.005Z"}, "contained": [{"resourceType": "Group", "id": "FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "name": "NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride", "description": "A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.", "type": "person", "membership": "enumerated", "characteristic": [{"code": {"text": "Research Study from which this is a flow group"}, "valueReference": {"display": "NCT03421379"}, "exclude": false}]}, {"resourceType": "Group", "id": "FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "name": "NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder", "description": "A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.", "type": "person", "membership": "enumerated", "characteristic": [{"code": {"text": "Research Study from which this is a flow group"}, "valueReference": {"display": "NCT03421379"}, "exclude": false}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-0-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-0-Period-1-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "STARTED at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 34}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-0-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-0-Period-1-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "STARTED at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 41}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-1-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-1-Period-1-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "Received at Least One Dose of Study Drug at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 33}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-1-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-1-Period-1-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "Received at Least One Dose of Study Drug at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 39}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-2-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-2-Period-1-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "COMPLETED at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 32}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-2-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-2-Period-1-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "COMPLETED at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 37}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-3-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-3-Period-1-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "NOT COMPLETED at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 2}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-3-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-3-Period-1-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "NOT COMPLETED at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 4}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-reason-Period-1-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-reason-Period-1-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "Reasons for withdraw at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "category": {"text": "Withdrawal by Subject"}, "quantity": {"value": 0}}, {"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "category": {"text": "Physician Decision"}, "quantity": {"value": 1}}, {"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "category": {"text": "Did not receive treatment"}, "quantity": {"value": 1}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-reason-Period-1-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-reason-Period-1-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "Reasons for withdraw at Period 1"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "category": {"text": "Withdrawal by Subject"}, "quantity": {"value": 1}}, {"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "category": {"text": "Physician Decision"}, "quantity": {"value": 1}}, {"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "category": {"text": "Did not receive treatment"}, "quantity": {"value": 2}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "STARTED at Washout Period (3 to 14 Days)"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 32}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "STARTED at Washout Period (3 to 14 Days)"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 37}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "COMPLETED at Washout Period (3 to 14 Days)"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 32}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "COMPLETED at Washout Period (3 to 14 Days)"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 37}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "NOT COMPLETED at Washout Period (3 to 14 Days)"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 0}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "NOT COMPLETED at Washout Period (3 to 14 Days)"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 0}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-0-Period-2-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-0-Period-2-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "STARTED at Period 2"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 32}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-0-Period-2-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-0-Period-2-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "STARTED at Period 2"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 37}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-1-Period-2-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-1-Period-2-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "COMPLETED at Period 2"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 32}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-1-Period-2-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-1-Period-2-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "COMPLETED at Period 2"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 37}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-2-Period-2-group-FG000", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-2-Period-2-group-FG000", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}}, {"variableRole": "outcome", "observed": {"display": "NOT COMPLETED at Period 2"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 0}}]}, {"resourceType": "Evidence", "id": "NCT03421379-flow-milestone-2-Period-2-group-FG001", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"]}, "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-flow-milestone-2-Period-2-group-FG001", "assigner": {"display": "Computable Publishing LLC"}}], "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2", "status": "active", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowEvidence", "display": "ParticipantFlowEvidence"}]}}], "variableDefinition": [{"variableRole": "population", "observed": {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}}, {"variableRole": "outcome", "observed": {"display": "NOT COMPLETED at Period 2"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "Count"}]}, "quantity": {"value": 0}}]}], "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "399871", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-participant-flow-report", "assigner": {"display": "Computable Publishing LLC"}}], "status": "final", "type": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ParticipantFlowReport", "display": "ParticipantFlowReport"}], "text": "Participant Flow Report"}, "author": [{"display": "[No author listed.]"}], "title": "Participant Flow Report for NCT03421379", "id": "399871", "url": "https://fevir.net/resources/Composition/399871", "date": "2025-12-11T11:42:09.005Z", "custodian": {"reference": "Organization/118079", "type": "Organization", "display": "Computable Publishing LLC"}, "relatesTo": [{"type": "cite-as", "targetMarkdown": "Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json."}], "section": [{"title": "Flow PreAssignment Details", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "participant-flow-details", "display": "Participant Flow Details"}], "text": "FlowPreAssignmentDetails"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.</div>"}}, {"title": "Flow Group List", "code": {"text": "FlowGroupList"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder</div>"}, "entry": [{"reference": "#FG000", "type": "Group", "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"}, {"reference": "#FG001", "type": "Group", "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"}]}, {"title": "STARTED at Period 1", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "STARTED at Period 1"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-0-Period-1-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1"}, {"reference": "#NCT03421379-flow-milestone-0-Period-1-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1"}]}, {"title": "Received at Least One Dose of Study Drug at Period 1", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "Received at Least One Dose of Study Drug at Period 1"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-1-Period-1-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1"}, {"reference": "#NCT03421379-flow-milestone-1-Period-1-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1"}]}, {"title": "COMPLETED at Period 1", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "COMPLETED at Period 1"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-2-Period-1-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1"}, {"reference": "#NCT03421379-flow-milestone-2-Period-1-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1"}]}, {"title": "NOT COMPLETED at Period 1", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "NOT COMPLETED at Period 1"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-3-Period-1-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1"}, {"reference": "#NCT03421379-flow-milestone-3-Period-1-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1"}]}, {"title": "Reasons for withdraw at Period 1", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "Reasons for withdraw at Period 1"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-reason-Period-1-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1"}, {"reference": "#NCT03421379-flow-reason-Period-1-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1"}]}, {"title": "STARTED at Washout Period (3 to 14 Days)", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "STARTED at Washout Period (3 to 14 Days)"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)"}, {"reference": "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)"}]}, {"title": "COMPLETED at Washout Period (3 to 14 Days)", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "COMPLETED at Washout Period (3 to 14 Days)"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)"}, {"reference": "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)"}]}, {"title": "NOT COMPLETED at Washout Period (3 to 14 Days)", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "NOT COMPLETED at Washout Period (3 to 14 Days)"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)"}, {"reference": "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)"}]}, {"title": "STARTED at Period 2", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "STARTED at Period 2"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-0-Period-2-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2"}, {"reference": "#NCT03421379-flow-milestone-0-Period-2-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2"}]}, {"title": "COMPLETED at Period 2", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "COMPLETED at Period 2"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-1-Period-2-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2"}, {"reference": "#NCT03421379-flow-milestone-1-Period-2-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2"}]}, {"title": "NOT COMPLETED at Period 2", "code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "results", "display": "Results"}], "text": "Participant Flow Results"}, "focus": {"display": "NOT COMPLETED at Period 2"}, "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "entry": [{"reference": "#NCT03421379-flow-milestone-2-Period-2-group-FG000", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2"}, {"reference": "#NCT03421379-flow-milestone-2-Period-2-group-FG001", "type": "Evidence", "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2"}]}]}